Michael R. Grunwald, MD, director of the leukemia section in the department of hematologic oncology and blood disorders at the Levine Cancer Institute, Atrium Health, discusses findings from the PLAT-02 trial, which showed that consolidative hematopoietic stem cell transplant after CD19-directed CAR T-cell therapy prolonged leukemia-free survival for certain patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia, particularly those who achieved complete remission after CAR T-cell therapy but remained at risk for relapse with a short term B-cell aplasia derived.